Over the weekend, Nuvalent, Inc. (NASDAQ:NUVL) highlighted the presentation of updated data from Phase 1 dose-escalation portions of the ongoing ARROS-1 Phase 1/2 trial of zidesamtinib and ALKOVE-1 Phase 1/2 trial of NVL-655, at the European Society for Medical Oncology (ESMO) Congress 2024.
In total, 227 patients were enrolled in the Phase 2 portion of the ARROS-1 trial of zidesamtinib for TKI-naïve and TKI-pretreated patients with advanced ROS1-positive NSCLC and other solid tumors. The company expects to report pivotal data from this trial in 2025.
The Phase 1 portion of ARROS-1 enrolled 104 heavily pretreated patients. As of the cut-off date of July 1, 71 pretreated patients with ROS1-positive NSCLC were response-evaluable.
In the overall patient population, the objective response rate (ORR) was 44%, with a duration ...
